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proliferation, migration and anchorage-independent cell
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Marina Bouche2,3, Pietro L Poliani1, Marika Vezzoli1, Francesca Longhena1, Eugenio Monti1, Barbara Salani4,
Davide Maggi4, Charles Keller5,6 and Alessandro Fanzani1,2
Rhabdomyosarcoma (RMS) is a childhood soft tissue tumor with broad expression of markers that are typically
found in skeletal muscle. Cavin-1 is a recently discovered protein actively cooperating with Caveolin-1 (Cav-1) in the
morphogenesis of caveolae and whose role in cancer is drawing increasing attention. Using a combined in silico and
in vitro analysis here we show that Cavin-1 is expressed in myogenic RMS tumors as well as in human and primary mouse
RMS cultures, exhibiting a broad subcellular localization, ranging from nuclei and cytosol to plasma membrane. In
particular, the coexpression and plasma membrane interaction between Cavin-1 and Cav-1 characterized the proliferation
of human and mouse RMS cell cultures, while a downregulation of their expression levels was observed during the
myogenic differentiation. Knockdown of Cavin-1 or Cav-1 in the human RD and RH30 cells led to impairment of cell
proliferation and migration. Moreover, loss of Cavin-1 in RD cells impaired the anchorage-independent cell growth in soft
agar. While the loss of Cavin-1 did not affect the Cav-1 protein levels in RMS cells, Cav-1 overexpression and knockdown
triggered a rise or depletion of Cavin-1 protein levels in RD cells, respectively, in turn reflecting on increased or decreased
cell proliferation, migration and anchorage-independent cell growth. Collectively, these data indicate that the interaction
between Cavin-1 and Cav-1 underlies the cell growth and migration in myogenic tumors.
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Rhabdomyosarcoma (RMS) is a childhood soft tissue sarcoma
exhibiting broad expression of skeletal muscle markers,1–3
such as Pax7, MyoD, Myogenin, desmin and muscle-specific
actin.4,5 Cells of origin in RMS may be different muscular and
non-muscular cell precursors,6–8 such as muscle satellite cells
(SCs),9–11 and myoblasts9,10,12–14 or adipocytes,15 which are
responsible of two major histological subtypes known as
embryonal (ERMS) and alveolar (ARMS). The most common
ERMS variant arises in children usually o5 years on distinct
body sites, such as head, neck and genitourinary regions,
while ARMS typically arises in the muscular limb extremities
of adolescents and is characterized by poorer prognosis.16 The
genomic landscape causative of ERMS is characterized by a
number of genetic lesions and/or somatic mutations that
deliberately sustain the activity of different receptors, such as
IGF1R, FGFR4 and Patched,17–21 and related downstream
pathways (i.e., RAS/ERK, PI3K/AKT and Sonic Hedgehog
signaling).11,22 In addition, defects in tumor suppressors
(i.e., p53),23 cell cycle regulatory genes (i.e., N-Myc, Rb1)21,24
and structural proteins involved in muscular integrity
(i.e., dystrophin, alpha-sarcoglycan and dysferlin) have
been reported.25–30 Conversely, ARMS is dominated by the
presence of specific chromosomal translocations leading
to expression of the fused Pax3-Foxo1 and Pax7-Foxo1
factors, that driving in a cell cycle manner the transcription
of several genes normally restricted to the embryonal
development favor tumor initiation in some muscle pre-
cursors.31–36
A number of important cellular processes, such as
endocytosis, cholesterol homeostasis and signal transduction,
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takes place in small invaginations of the plasma membrane
known as caveolae,37 specialized microdomains whose
morphogenesis and function depend on the complex network
established between two protein families known as Caveolins
(Cav-1, Cav-2 and Cav-3)38–40 and Cavins (Cavin-1, -2, -3
and -4).41–44 In particular, deficiency of either Cav-145 or
Cavin-146–48 has been reported to cause global loss of caveolae
in different tissues. Cav-1 is a scaffolding protein that forms
supramolecular complexes anchored to the inner leaflet of the
plasma membrane and has been historically reported to be
sufficient for de novo formation of caveolae in both caveolae-
deficient cells49 and bacteriae.50 Cavin-1 was instead recently
discovered as a soluble protein stabilizing Cav-1 oligomers
and presumably facilitating their membrane insertion
underlying the generation of the characteristic caveolar
profile.46,47,51 Altered expression levels and gene mutations
affecting stability and/or localization of these proteins have
been widely reported to be causative of various diseases,
ranging from lung diseases and muscular dystrophies to
cancer. In RMS, we have previously shown that Cav-1
expression is often associated to a cell status of scarce
differentiation.52,53 More recently, we have also shown that
high Cav-1 protein levels enhance RMS tumor growth and
chemoresistance, whereas Cav-1 depletion limits cell prolif-
eration, migration and invasion as well as sensitizes RMS cells
to chemotherapy drug-induced apoptosis.54 Here we have
used a combined in silico and in vitro approach to address the
question of whether Cavin-1 may be expressed and have a
role in RMS. To this purpose, we have used human RMS cell
lines as well as primary mouse tumor cultures established
from transgenic mouse models faithfully recapitulating the
onset and progression of RMS. Our findings unveil that
Cavin-1, forming plasma membrane complexes with Cav-1,
contributes in sustaining proliferation, migration and
anchorage-independent growth of RMS cells.
MATERIALS AND METHODS
All reagents were from Sigma-Aldrich (Milan, Italy), unless
otherwise stated. Cell culture materials were purchased from
Jet-Biofil (Carlo Erba Reagents-Dasit Group, Cornaredo,
Italy).
Microarray Gene Expression Data Analysis
All analyses of microarray gene expression data were
performed with the Partek Genomics Suite software version
6.6 (Partek, St Louis, MO, USA). Briefly, the microarray raw
data set with the accession number GSE2252010 deposited in
the NCBI Gene Expression Omnibus database were repro-
cessed by background correction, normalization and sum-
marization of probe intensities using the robust multiarray
average analysis to determine the specific hybridizing signal
for each probe set. After background correction, the data
expression of each probe was corrected for perfect match
intensity and was transformed in base-2 logarithm.55 Quality
control was performed by investigating principal component
analysis to detect grouping patterns in the samples and to
identify the outliers and evaluate whether batch effect signifi-
cantly affected the data. To detect differentially expressed
genes (DEGs) between mouse ARMS/ERMS vs normal muscle
samples, a one-way analysis of variance (ANOVA) was per-
formed. To assess significant differences in the gene expression
profile in all groups, we selected the genes that had more than
a 2.0-fold change (|FC|≥ 2.0) and P-values o0.05. Multiple
testing correction was applied to control the false-discovery
rate using the Benjamini–Hochberg procedure. All corrected
P-values o0.05 were considered significant.
Histological and Immunofluorescence Analyses
Muscle cryosections were fixed in 4% paraformaldehyde
(PFA) on ice. Immunofluorescence analysis of cryosections
was performed as previously described.56 Nuclei were counter-
stained with Hoechst 33342 (Fluka, Sigma-Aldrich) or with
TO-PRO-3 (Invitrogen, Life Technologies, Monza, Italy), and
the samples were analyzed under an epifluorescence Zeiss
Axioskop 2 Plus microscope (Carl Zeiss, Oberkochen,
Germany) or a Leica Leitz DMRB microscope fitted with a
DFC300FX camera (Leica, Wetzlar, Germany).
Muscle Satellite Cell Cultures and Tumor Cultures
Primary mouse SCs were prepared from 1–2-week postnatal
mouse limbs as described previously.56 The cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 20% horse serum (HS) and 5% chick embryo
extract (EE). To induce differentiation, the cells were shifted
to DMEM supplemented with 5% HS and 1.25% EE for 3–
5 days. Human embryonal RD cells were purchased from the
European Collection of Cell Cultures. RD cells harbor
activating or inactivating RAS and p53 mutations, respec-
tively.57–59 Human RD12 and RD18 clonal cell lines, provided
by PL Lollini (University of Bologna, Italy), were derived by
random cloning of the human RD cell line.60,61 Human RH30
cells have a tetraploid karyotype and harbor both the Pax3-
Foxo1 signature derived from the t(2;13) translocation62 and
p53-inactivating mutations.59 The primary mouse ERMS and
ARMS cultures, namely, U57810 and U23674, respectively,
have been derived from transgenic mice harboring either loss
of p53 or concomitant loss of p53 and knock-in of Pax3-
Foxo1 in Myf6-positive differentiating myoblasts, respec-
tively.10,13 Tumor cells were routinely maintained under
standard conditions (37 °C and 5% CO2 in humidified
incubator) in a growth medium (GM), composed of high-
glucose DMEM supplemented with 10% fetal bovine serum
(FBS) and 100 μg/ml penicillin–streptomycin antibiotics, in
the presence of 1% L-glutamine (only for RH30 and U23674
cells). To induce myodifferentiation, 80% confluent cells were
switched to a differentiating medium (DM), composed of
DMEM supplemented with 2% HS. Cells received the
chemical PD098059 (10 μM, dissolved in dime-
thylsulfoxide vehicle), a synthetic upstream inhibitor of the
RAS/ERK cascade, the pan-phosphatase inhibitor Na3VO4
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(20 μM, dissolved in water) and the chemotherapy drug
doxorubicin (0.15 ng/ml, dissolved in water).
RNA Isolation and Semi-Quantitative RT-PCR Analysis
Total RNA was isolated using a Tri-reagent kit and treated
with DNA-free DNase (Promega, Madison, WI, USA). RNA
(2 μg) was reverse transcribed in the presence of 400 Units of
Moloney murine leukemia virus reverse transcriptase enzyme
(Promega) and the obtained cDNA template was used for
PCR analysis using specific forward and reverse primers
(250 nM) annealing to both human and mouse sequences. In
particular, a 424-bp-long Cavin-1 fragment was amplified
Figure 1 Analysis of Cavin-1 in skeletal muscle and in muscle satellite cells (SCs). (a) Immunofluorescence analysis was carried out on mouse
cryosections from tibialis anterior skeletal muscle to analyze distribution of Cavin-1 (red), using MHC (green) as marker of differentiated myofibers. The
counterstaining with DAPI reactive was used to visualize cell nuclei. BVs stands for blood vessels. (b) Purified SCs were seeded in 60mm dishes (at a
density of 12 × 104 cells) and cultured in GM until confluence, followed by incubation in DM. After 72 h in GM or DM, cells were harvested and protein
homogenates subjected to centrifugation for separating membranous from soluble fractions. Equal amounts of proteins were then western blotted for
Cavin-1, Cav-3 and tubulin. Protein bands were quantified by densitometry after normalization with respect to tubulin (n= 3). **Po0.001; ***Po0.0001.
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with 5′-ATCAAGAAGCTGGAGGTCAACGAG-3′ and 5′-TC
TCAGGTTTTCCTTGGTCTTGA-3′ primers, a 103-bp-long
Cav-1 fragment with 5′-AACCGCGACCCTAAACACCT-3′
and 5′-CCTTCCAAATGCCGTCAAAA-3′ primers and a




Knockdown constructs were purchased from Tema-Ricerca/
Origene (Castenaso, Italy) in pRS backbone: shCavin-1 #1
(clone TR310045A–TI340173, 5′-ATGATCTACCAGGATG
AAGTGAAGCTGCC-3′); shCavin-1 #2 (clone TR310045B–
TI340174, 5′-CGCAAGGTCAGCGTCAACGTGAAGACCGT-3′);
shCavin-1 #3 (clone TR310045C–TI340175, 5′-CACCTTCC
ACGTCAAGAAGATCCGCGAGG-3′). As negative control,
pRS-puro vector harboring the off-target sequence (clone
TR30012, 5′-GCACTACCAGAGCTAACTCAGATAGTACT
-3′) was used. Cav-1 overexpression and knockdown were
obtained as previously described in Faggi et al.54 Cells were
stably transfected using Transit-LT1 reagent (Tema-Ricerca)
according to the manufacturer’s protocol. After antibiotic
selection, the experiments produced similar results in all the
selected clones.
Antibodies
The following primary antibodies were used: rabbit anti-
Cavin-1 (AbCam, Cambridge, UK, 1:3000 dilution) for
immunoblotting and immunofluorescence analyses; rabbit
anti-Cavin-1 (ThermoScientific, Waltham, MA, USA) for
immunoprecipitation assay; rabbit anti-Cav-1 (Santa Cruz
Biotechnology, Dallas, TX, USA, 1:1000 dilution); mouse
anti-Cav-1 (Zymed-Life Technologies, Monza, Italy, 1:100
dilution); mouse anti-MHC (Santa Cruz Biotechnology,
1:1000 dilution); mouse anti-Cav-2 (BD, Buccinasco, Italy,
1:1000 dilution); mouse anti-Cav-3 (BD, 1:1000 dilution);
mouse anti-total and -phosphorylated ERK1/2 (Tyr204)
(Santa Cruz Biotechnology, 1:1000 dilution); mouse anti-
alpha-tubulin (Sigma-Aldrich, 1:10 000 dilution).
Immunoblotting and Immuneprecipitation Analyses
Protein concentration was calculated by Bradford reagent
assay. Equal amounts of protein samples were separated by
SDS–PAGE under reducing conditions and transferred to
polyvinylidine fluoride membranes. Incubation with specific
primary antibodies was followed by horseradish peroxidase-
conjugated secondary antibodies, including goat anti-mouse
IgG (Santa Cruz Biotechnology) and donkey anti-rabbit IgG
from Thermo Scientific-Pierce, Erembodegem, Belgium), and
the resulting immune complexes were visualized using
enhanced chemiluminescence reagent (GeneSpin, Milan,
Italy). Immune-reactive bands were quantified using densito-
metric analyses (Software Gel Pro Analyzer, version 4). For
detection of Cavin-1, myosin heavy chain (MHC) and
tubulin, total homogenates were prepared by harvesting the
cells in cold RIPA lysis buffer, composed of 20 mM Tris-HCl
(pH 7.6), 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM NaCl, and a cocktail of protease inhibitors
(Roche, Monza, Italy) plus phosphatase inhibitors (1 mM
Na3VO4 and 4 mM NaF). Total homogenates were then
centrifuged at 12 000 g for 10 min at 4 °C. For detection of
Caveolins, the Triton-insoluble membranous fractions were
obtained by harvesting the cells in a cold Triton buffer,
composed of 10 mM Tris-HCl (pH 8.0), 1% Triton X-100,
5 mM EDTA, 150 mM NaCl and a cocktail of protease
inhibitors plus phosphatase inhibitors, followed by centrifu-
gation (15 000 g for 15 min at 4 °C).
For immunoprecipitation analysis, the cells were lysed in a
buffer composed of 50 mM Tris-HCl buffer (pH 7.4),
containing 150 mM NaCl, 1% Triton X-100 and a cocktail
of protease and phosphatase inhibitors, followed by incuba-
tion for 20 min at 4 °C. After centrifugation (10 min, 11 500 g
at 4 °C), supernatants were pre-cleared with protein G–
Sepharose (20 μl/sample, GE Healthcare, Fairfield, CT, USA)
for 1 h. Cell extracts (1 mg aliquots) were incubated overnight
with bland agitation at 4 °C with rabbit polyclonal anti-Cav-1
Figure 1 Continued.
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Figure 2 In silico analysis of Cavin-1 and Caveolins transcriptional levels in mouse RMS tumors. (a) Representative dot plot of the mRNA expression
levels of Cavin-1, Cav-1, Cav-2 and Cav-3 genes in ARMS, ERMS and normal muscle samples. In the plot, each dot is a sample of the original data. The
y-axis represents the log2-normalized intensity of the gene and the x-axis represents the different types of samples. Bars represent the average ± s.e.m.
(b) Venn diagram depicts the overlap between differentially expressed transcripts (≥ 2-fold expression; Po0.05) in ARMS or ERMS vs normal muscle.
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(5 μl/sample, Santa Cruz Biotechnology) or rabbit anti-Cavin-
1 (10 μl/sample, ThermoScientific). Immune complexes were
then recovered on protein G–Sepharose (1 h with bland
agitation at 4 °C), centrifuged (1 min, 14 000 g) and washed
four times with lysis buffer and twice with the same buffer
without Triton X-100. Proteins were then analyzed on
nonreducing SDS–12% PAGE followed by immunoblotting
with anti-Cavin-1 and anti-Cav-1 antibodies. The enhanced
chemiluminescence technique (Genespin) was used for
detection. As positive control, 30 μg of total homogenates
was loaded, whereas 30 μg of pre-cleared sample was loaded
as negative control.
Figure 3 In vitro analysis of Cavin-1 and Caveolins protein levels in human RMS lines and primary mouse tumor cultures. (a) Cavin-1 and Caveolins
protein levels were analyzed in two primary mouse tumor cultures (embryonal U57810 and alveolar U23674) established from conditional transgenic
mice and four human RMS cell lines (embryonal RD, RD12, RD18 and alveolar RH30). Cells were seeded in 60mm dishes (at a density of 12 ×104 cells)
and cultured in GM until confluence, followed by incubation in DM. After 72 h in GM or DM, cells were harvested and protein homogenates western
blotted for Cavin-1, Caveolins, MHC and tubulin. Protein bands were quantified by densitometry after normalization with respect to tubulin (n= 3).
*Po0.05; **Po0.001; ***Po0.0001. (b) Confocal microscopy analysis was employed to analyze the distribution of Cavin-1, Cav-2 and Cav-3 in RMS cells.
Human RD cells cultured in GM for 72 h were fixed, permeabilized and immunostained with antibodies against Cavin-1, Cav-1 and Cav-2 followed by
anti-rabbit and anti-mouse Cy3, respectively. Alternatively, confluent RD cells were cultured in DM for 72 h and then fixed, permeabilized and
immunostained with antibodies against Cavin-1 and Cav-3 followed by anti-rabbit Alexa488 and anti-mouse Cy3, respectively.
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Immunofluorescence Analysis
Cells were cultured onto 12 mm glass coverslips coated with
FBS (Carlo Erba Reagents-Dasit Group, Cornaredo, Italy) and
fixed with PFA for 15 min at room temperature. PFA was
then quenched incubating the cells in NH4Cl (50 mM) for
additional 15 min. Cells were then washed with phosphate
buffer solution (PBS)/sucrose (2%) and treated with 0.1%
Triton X-100 to allow cell permeabilization. Cells were then
treated three times with 3% bovine serum albumin in PBS for
10 min, and incubated for 3 h in a humidified atmosphere
with the Cav-1 antibody (1:300 dilution), Cavin-1 antibody
(1:200 dilution) alone or in the presence of the mouse Cav-1
antibody (1:100 dilution, purchased from Zymed-Life Tech-
nologies), Cav-2 antibody (1:100 dilution, purchased from
BD) or Cav-3 antibody (1:200 dilution, purchased from BD).
After PBS washing, samples were incubated for 1 h with a
diluted 1:500 anti-rabbit CY3-conjugated and/or anti-mouse
Alexa 488 streptavidin-conjugated secondary antibody (Jack-
son ImmunoResearch Laboratories, West Grove, PA, USA).
Hoechst staining (1:1000 in sterile water) was employed to
visualize the cell nuclei. Cells were analyzed using a Zeiss
Axiovert 200M epifluorescence microscope equipped with
Apotome or a LSM510 Meta confocal microscope, using a
Plan-Apochromat × 63/1.4 NA oil objective (Carl Zeiss).
Digital images were further examined using AxioVision
‘Extended Focus Acquisition’ module and AxioVision
‘Inside4D’ module software (Carl Zeiss).
Cell Proliferation Assay
Cells were seeded into 24-well plates (at a density of 15 × 103
cells). After 48 or 72 h, cells were harvested, PFA-fixed and
stained with Crystal violet (0.5% in PBS with 20% methanol).
Figure 3 Continued.
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Absorbance was then measured by reading the plate at
570 nm emission wavelength. The growth rate was calculated
using Microsoft Excel 2010 software. Images of cell prolifer-
ation assays reflect representative results of at least three
independent experiments.
Chemotaxis Assay
Cells (25 × 103 in 50 μl of DMEM with 5% FBS) were seeded
in the upper compartment of a Boyden chamber, containing
gelatin-coated PVP-free polycarbonate filters (8 μm pore size,
Costar-Corning, Tewksbury, MA, USA) and DMEM with
10% FBS in the lower compartment. As a negative control,
1% FBS medium was used. After 5 h of incubation at 37 °C,
cells migrated to the lower side of the filter were stained with
Diff-Quik (Dade-Behring, GE Healthcare). Five random fields
were counted for each triplicate sample.
Cell Viability Assay
The lysosomal accumulation of neutral red dye was used to
evaluate the percentage of viable cells.63,64 Briefly, the cells
were seeded into 96-well plates (at a density of 1.5 × 103 cells).
After 24 h, cells received doxorubicin (0.15 ng/ml) for 48 h,
before incubation for 2 h with neutral red dye (40 μg/ml)
dissolved in DMEM with 5% FBS. Cells were then washed
with PBS and 100 μl of elution medium (50% ethanol and 1%
acetic acid), followed by gentle shaking for 10 min so that
complete dissolution was achieved. Absorbance was then
measured by reading the plate at 540 nm emission wave-
length. Results are presented as percentage of control values.
Images of cell viability assays reflect representative results of at
least three independent experiments.
Soft Agar Colony Formation Assay
Control RD cells and clones (overCav-1, shCav-1 and
shCavin-1) were suspended in 1 ml of medium containing
0.3% agar and applied onto 2 ml of presolidified 0.6% agar
plus 20% FBS in six-well plates (10 × 105 cells/well). After 1–2
and 3 weeks of incubation, colonies were observed under a
phase contrast microscope, photographed and counted. The
results were expressed as the mean± s.d. of triplicate counts
within the same experiment.
Statistical Analysis
The differences between the groups were analyzed by
unpaired Student’s t-tests and one-way ANOVA test (with
Dunnet’s post test), using Prism 4 software for Windows
(GraphPad Software). Statements of significance were based
on a P-value of o0.05.
Results
Cavin-1 is Expressed in Skeletal Muscle as well as in
Myogenic RMS Tumors
Immunofluorescence experiments were performed to analyze
Cavin-1 distribution in mouse skeletal muscle. In cryosections
from tibialis anterior muscle, Cavin-1 staining was expectedly
found labeling endothelial cells in the blood vessels (BVs)
(Figure 1a). In addition, Cavin-1 staining was localized in
mononucleated cell elements surrounding the myofibers as
well as at the plasmalemma of myofibers positive for MHC
(Figure 1a). As the pool of mononucleated cells residing
interposed among the myofibers may comprise several cell
elements of different origin, including muscle SCs, fibroadi-
pogenic progenitors and mesenchymal stem cells,65 we
decided to address the question of whether Cavin-1 was
specifically present in SCs. To this purpose, the protein levels
of Cavin-1 were analyzed in ex vitro experiments using SCs
isolated from mouse skeletal muscle. Immunoblotting
analysis carried out on membranous and soluble cell fractions
showed the presence of Cavin-1 in proliferating SCs as well as
its incremented expression during the myogenic differentia-
tion, which was characterized by raised levels of Cav-3
(Figure 1b). Given the presence of Cavin-1 in skeletal muscle,
we decided to evaluate whether Cavin-1 might be present in
RMS, further evaluating the levels of Caveolins because of
their close relationship.46 To this purpose, we employed an in
silico approach taking advantage of microarray data that have
been previously generated by the analysis of RMS tumors
arisen in mouse models with specific genetic alterations.10 As
shown by dot plot graphs (Figure 2a), the relative levels of
Cavin-1 and Caveolins, as detected in ARMS (n= 14) and
ERMS (n= 7) tumors, were similar to those found in skeletal
muscle samples (n= 4) (Figure 2a). As represented by the
Venn diagram, this in silico analysis allowed to identify 3136
and 2322 DEGs in ARMS and ERMS tumors with respect to
skeletal muscle (fold-change ≥ 2, corrected P≤ 0.05), respec-
tively (Figure 2b). The analysis essentially indicated that
Cavin-1, Cav-1 and Cav-2 were expressed in a similar manner
in tumors and skeletal muscle, while only Cav-3 fell into the
subset of DEGs that were significantly downregulated in
ARMS compared with skeletal muscle (Figure 2b). We then
Figure 4 Expression analysis of Cavin-1 and Caveolins in RD and RH30 lines upon cell cycle arrest or myogenic differentiation induced by
pharmacological treatments. (a) RD and RH30 cells were seeded into 24-well plates (at a density of 15 × 103 cells). After 24 h, cells were treated with
10 μM PD098059 (renewed every 24 h) or 20 μM Na3VO4 (administered only once) for up to 48 h. Cell proliferation was evaluated by Crystal violet assay.
Histograms represent means ± s.d. of growth rate index (n= 3). *Po0.05; **Po0.001. (b) Under the same conditions seen above, equal amounts of
proteins derived from untreated and treated cells for 24 and 48 h were then western blotted for Cavin-1, Caveolins, MHC and tubulin (n= 3). Protein
bands were quantified by densitometry after normalization with respect to tubulin (n= 3). (c) Subconfluent RD cells were mantained in DM over a 72-h-
long time-course, in the absence or presence of daily administered 10 μM PD098059. Cells were then harvested and protein homogenates western
blotted for Cavin-1, Caveolins, MHC, ERK1/2 (phosphorylated and total forms) and tubulin. Protein bands were quantified by densitometry after
normalization with respect to tubulin (n= 3). **Po0.001.
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Figure 5 Confocal microscopy analysis of Cavin-1 and Cav-1 subcellular localization. Confocal microscopy analysis was employed to analyze distribution
of Cavin-1 and Cav-1 in RD cells. (a) Cavin-1 and Cav-1 localization was highlighted by means of the extended focus Z stack image (14 slides of
0.32 μm), combining each visual plane with the AxioVision software (left panels). Pictures were taken at × 63 magnification. To outline the nuclear
localization of Cavin-1, the clipped three-dimensional images (3D and YZ clip 3D images, respectively) were created, as depicted in the green rectangles
(right panels), using the Inside4D function of AxioVision software 3D. (b) The cell surface colocalization of Cavin-1 and Cav-1 was outlined by using the
colocalization module of AxioVision software. The graph shows the fluorescence intensity profiles of Cavin-1 (red curve) and Cav-1 (green curve) along
the regions indicated by the white straight-line in the picture. (c) Either endogenous Cav-1 or Cavin-1 was immunoprecipitated in cell lysates (1 mg)
derived from human and mouse cell lines cultured in GM or DM for 72 h. Co-immunoprecipitated Cavin-1 or Cav-1 were then detected by
immunoblotting. Pre-cleared samples and homogenates were loaded as negative and positive control, respectively. Results are representative of three
independent experiments.
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analyzed the protein expression by immunoblotting using
different RMS lines, including two primary tumor cultures
established from RMS-bearing transgenic mice10 and four
human RMS cell lines (see Materials and Methods for the
genetic background characterizing each line). In mouse and
human cells, the molecular weight of Cavin-1 protein band
was ~ 43 and 50 kDa, respectively (Figure 3a). In particular,
Cavin-1 was always recognized in concomitance with Cav-1
and Cav-2 in cells cultured in GM, while stimulating a
variable degree of myogenic differentiation by culturing the
cells in DM for 3 days led to downregulation of Cavin-1, Cav-
1 and Cav-2 followed by upregulation of Cav-3 and MHC
levels (Figure 3a). By immunofluorescence analysis we
observed that Cavin-1 partially colocalized with either Cav-1
or Cav-2 during cell proliferation, as shown in RD cells
(Figure 3b, upper panels). Conversely, Cavin-1 and Cav-3 did
not colocalize, as observed during myodifferentiation of RD
cells (Figure 3b, bottom panels). Analogous results were also
observed in RH30 cells (not shown).
Cavin-1, Cav-1 and Cav-2 Downregulation is Specifically
Related to Myogenic Differentiation of RMS Cells
To understand whether Cavin-1, Cav-1 and Cav-2 down-
regulation might be specifically related to the block of cell
cycle rather than differentiation, we treated proliferating RD
and RH30 cells with PD098059 or Na3VO4, which were
reported to affect RMS cell proliferation via inhibition of the
ERK signaling and phosphatase activity, respectively.66–68 As
determined by Crystal violet assay, either treatment was
effective in reducing cell proliferation in comparison to
vehicle-treated cells (Figure 4a), but without affecting the
protein levels of Cavin-1, Cav-1 and Cav-2, as shown by
immunoblotting and relative densitometric analysis
(Figure 4b). In these conditions, the inhibition of prolifera-
tion was not accompanied by concomitant differentiation, as
the expression levels of Cav-3 and MHC were always
undetectable (Figure 4b). Conversely, forcing the myogenic
differentiation of RD cells by co-treatment with DM and
PD098059 led to reduction in Cavin-1, Cav-1 and Cav-2
protein levels followed by increased levels of Cav-3 and MHC
(Figure 4c).
These data suggest that concomitant presence of Cavin-1,
Cav-1 and Cav-2 is mainly predictive of RMS cell growth,
whereas downregulation of their protein levels seems to be a
consequence of the differentiation program.
Cavin-1 Interacts with Cav-1 at the Plasma Membrane of
ERMS and ARMS Cells
Confocal microscopy analysis was used to evaluate the
subcellular localization of Cavin-1 and Cav-1 in RD cells.
As shown in Figure 5a (left panels), Cavin-1 exhibited a broad
cellular distribution, ranging from nuclei (highlighted via
three-dimensional reconstruction images in the right panels)
and cytosol to plasma membrane, whereas Cav-1 was more
localized at the plasma membrane and to a lesser extent in the
cytosol. Colocalization of Cavin-1 with Cav-1 was specifically
detectable at the plasma membrane, as shown in merged
images (yellow color) (Figure 5b). Moreover, Cav-1 and
Figure 5 Continued.
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Cavin-1 partially colocalized also at the perinuclear regions
presumably corresponding to Golgi apparatus, where both
nascent proteins are synthesized.43
To address the question of whether Cavin-1 and Cav-1
might specifically interact, we also carried out immunopre-
cipitation of endogenous Cav-1 or Cavin-1 followed by
immunoblotting against Cavin-1 and/or Cav-1 using the cell
extracts obtained from four human and mouse RMS cell lines.
These experiments clearly show that Cavin-1 and Cav-1
physically interact, especially during cell growth (Figure 5c).
Overall, these data suggest that Cavin-1 and Cav-1 form
protein complexes at the plasma membrane of proliferating
RMS cells.
Cavin-1 Knockdown Decreases Cell Proliferation and
Migration in the Embryonal RD and Alveolar RH30 Cell
Lines
To determine whether loss of Cavin-1 might affect the
behavior of RMS cells, we knocked down Cavin-1 expression
in human RD and RH30 cells. To this purpose, we selected
different clones in which the transcript and protein levels of
Cavin-1 were downregulated by stable delivery of shCavin-1
vectors in comparison to shOFF target (i.e., shOT) constructs,
as shown by semiquantitative PCR and immunoblotting
(Figure 6a). By immunofluorescence analysis, Cavin-1 label-
ing was consistently reduced at the plasma membrane and in
the cytosol of shCavin-1 clones in comparison to shOT cells,
with a residual signal remaining barely detectable in the nuclei
of RD cells (Figure 6b).
As Cavin-1 depletion has been reported to trigger Cav-1
mislocalization followed by protein degradation,69 we eval-
uated the expression and localization of Cav-1 in shCavin-1
clones. In both RD and RH30 lines, there was no significant
difference in Cav-1 transcript and protein levels between
shCavin-1 and control shOT clones, as detected via
semiquantitative PCR and immunoblotting (Figure 6a).
Immunofluorescence analysis showed that the loss of Cavin-
1 triggered an intracellular accumulation of Cav-1 in RD cells,
which gave rise to a marked staining at the perinuclear
regions (Figure 6b, upper panels). In addition, shCavin-1
clones in RD cells exhibited a residual nuclear staining
(Figure 6b). Indeed, nuclear proteins are more resistant to
knockdown mediated by shRNA because of the reduced
availability of RNAi cellular machinery into the nucleus.70 In
contrast, Cavin-1 downregulation in RH30 cells did not affect
the subcellular localization of Cav-1 (Figure 6b, bottom
panels). We next assayed the cell proliferation, migration and
chemoresistance of the different clones by means of the
Crystal violet, Boyden chamber and Neutral Red assays,
respectively. We observed that shCavin-1 clones exhibited a
significant impairment of cell proliferation and migration in
comparison to shOT cells, in both RD and RH30 lines
(Figure 6c). Conversely, the loss of Cavin-1 did not affect the
chemoresistance to doxorubicin in comparison to shOT cells
(Figure 6c).
Collectively, these data indicate that Cavin-1 depletion
significantly impairs the proliferation and migration, but not
chemoresistance, of the embryonal RD and alveolar
RH30 cells.
The Modulation of Cav-1 Expression Impacts the Cavin-1
Levels and the Cancerous Behavior of the RD Cell Line
We have recently demonstrated that Cav-1 overexpression
favors RMS growth, migration and chemoresistance, whereas
Cav-1 depletion inhibits cell growth and migration, further
sensitizing RMS cells to cell apoptosis induced by chemother-
apy drugs.54 Hence, we used specific RD clones in which Cav-
1 has been overexpressed or knocked down (overCav-1 and
shCav-1 clones, respectively) to analyze the effects on Cavin-1
expression and cellular localization. Cav-1 overexpression or
knockdown yielded increased or decreased protein levels of
Cavin-1, respectively, as shown via immunoblotting
(Figure 7a). Furthermore, immunoprecipitation experiments
clearly showed that the amount of Cavin-1 and Cav-1
complexes was increased in Cav-1-overexpressing RD cells
(Figure 7b). Immunofluorescence analysis showed that Cav-1
overexpression, yielding an increased Cav-1 staining at the
plasma membrane as well as in intracellular perinuclear
regions, resulted in an increased and diffused intracellular
Figure 6 Characterization of human RD and RH30 cells after Cavin-1 knockdown. After stable transfection with either shCavin-1 or shOT constructs, the
antibiotic-resistant clones were subjected to evaluation of Cavin-1 and Cav-1 expression levels. To this purpose, cells seeded in 60mm dishes (at a
density of 12 × 104 cells) were maintained for 48 h in GM and then harvested. (a) Semi-quantitative PCR and immunoblotting analyses with relative
densitometries showing the transcript and protein levels of Cavin-1 and Cav-1 in shOT and shCavin-1 clones of RD (left panels) and RH30 (right panels)
lines. Gapdh amplification was used to normalize the transcript levels. *Po0.05; **Po0.001; ***Po0.0001. Protein bands were quantified by
densitometry after normalization with respect to tubulin (n= 3). **Po0.001. (b) shCavin-1 and shOT clones were seeded onto coverslips (at a density of
10 × 104 cells) and maintained in GM for 72 h. Immunofluorescence analysis was then performed to visualize Cavin-1 and Cav-1 distribution in
RD (upper panels) and RH30 (bottom panels) lines. Hoechst staining (blue) was employed to visualize the cell nuclei. Pictures were taken at × 63
magnification. (c) Cell proliferation, migration and chemoresistance were evaluated in RD (left panels) and RH30 (right panels) lines after Cavin-1
knockdown. Cell proliferation was evaluated by Crystal violet assay. Histograms represent means ± s.d. of growth rate index (n= 4). *Po0.05; **Po0.001;
***Po0.0001. Cell migration was evaluated using a modified Boyden chamber assay. The migration index was calculated through the ratio between the
mean number of migrated shCavin-1 clones with respect to controls, as counted in five randomly chosen fields (n= 3). **Po0.001. Chemoresistance was
evaluated by means of neutral red assay in the absence or presence of 0.15 ng/ml doxorubicin for 24 h. Histograms represent means ± s.d. of viable cells
with respect to vehicle-treated cells (n= 4).
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Figure 7 Evaluation of levels and subcellular distribution of Cavin-1 after Cav-1 overexpression or knockdown. Human RD cells were stably transfected
with either Cav-1 construct (overCav-1) or shCav-1 construct plus relative mock and shOT vectors, respectively. (a) Cells seeded in 60 mm dishes (at a
density of 12 × 104 cells) were maintained for 48 h in GM and then harvested. The relative protein homogenates were immunoblotted for Cavin-1, Cav-1
and tubulin. Protein bands were quantified by densitometry after normalization with respect to tubulin (n= 3). **Po0.001; ***Po0.0001. (b) Endogenous
Cav-1 or Cavin-1 was immunoprecipitated in cell lysates (1 mg) of the different clones cultured in GM for 72 h. Co-immunoprecipitated Cavin-1 or Cav-1
was then detected by immunoblotting. Pre-cleared samples and homogenates were loaded as negative and positive control, respectively. Results are
representative of three independent experiments. (c) OverCav-1 and shCav-1 clones plus relative controls were seeded onto coverslips (at a density of
10 × 104) and maintained in GM for 72 h. Immunofluorescence analysis was then performed to visualize Cav-1 (green) and Cavin-1 (red) distribution.
Hoechst staining (blue) was employed to visualize the cell nuclei. Pictures were taken at × 63 magnification.
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Cavin-1 staining (Figure 7c). Conversely, Cav-1 depletion led
to almost complete loss of Cavin-1 staining (Figure 7c).
Taken together, these data suggest that the levels of Cav-1
seem to influence those of Cavin-1 and not vice versa, at least
in RD cells.
Cavin-1 and Cav-1 are Both Required to Confer
Anchorage-Independent Cell Growth in the RD Line
Normal cells require a solid substratum to proliferate,
whereas malignant cells gain the ability to grow regardless
of their attachment status. In this regard, the cell anchorage-
independent growth represents an important hallmark
predictive of cellular transformation.
To address the question of whether Cavin-1 and Cav-1 may
contribute to anchorage-independent cell growth, we per-
formed a soft agar colony formation assay using RD cells.
Either loss of Cavin-1 or Cav-1 was detrimental to anchorage-
independent cell growth, as shCavin-1 clones formed fewer
colonies (Figure 8a), whereas shCav-1 clones had completely
lost the ability to form colonies in comparison to control
shOT cells (Figure 8b). Conversely, Cav-1-overexpressing
cells more quickly formed highly dense colonies in compar-
ison to mock cells (Figure 8c).
These data indicate that loss of either Cavin-1 or Cav-1
impairs the ability of RD cells to grow in an anchorage-
independent manner, whereas the gain of Cav-1 and the
concomitant increase of Cavin-1 correlated with an incre-
mented anchorage-independent cell growth.
DISCUSSION
Cavin-1, also known as polymerase transcription released
factor, is a soluble protein that was originally identified as a
nuclear factor cooperating with RNA polymerase I during the
transcription process71,72 as well as interacting with the
BFCOL1 (binding factor of a type-I collagen promoter) zinc-
finger transcription factor.73 Since then, Cavin-1 was also
identified in lipid rafts,74 especially in adipocytes,75–78 where
it has an active role during hormone-sensitive lipolysis.77,78
Over the past years some works have unveiled that this
versatile protein even specifically cooperates with Cav-1 in the
morphogenesis of caveolae,74–78 specialized microdomains of
the plasma membrane that in several cell types represent the
primary sites of important processes such as the endocytosis
and signal transduction.37 In particular, Cavin-1 seems to
have a pivotal role as protein cargo facilitating the transport of
Cav-1 oligomers from the Golgi compartments toward the
plasma membrane, whereby their insertion into the inner
membranous leaflet actively participates in the establishment
of caveolar domains by triggering the membrane curvature.
Consistent with this, loss of either Cavin-1 or Cav-1 in mouse
models triggers the flattening of caveolar domains and reflects
in partially overlapping phenotypes characterized by the onset
of different diseases. For example, deficiency of Cavin-1 in
skeletal muscle has been associated with human lipodystro-
phy, muscular dystrophy and cardiac dysfunction.79–84 In
accordance, mice lacking Cavin-1 exhibit a lipodystrophic
phenotype48 as well as an altered metabolic flux among
multiple tissues, which suggests a role of Cavin-1 in the
coordination of peripheral glucose and fatty-acid storage and
utilization.85
Figure 8 Analysis of the anchorage-independent cell growth in
engineered RD cells. A soft agar assay was performed to evaluate the
ability of RD cells to grow in a substrate-independent manner after
knockdown of Cavin-1 (a) or Cav-1 (b) and overexpression of Cav-1 (c).
Values obtained by quantification of the colony numbers are the
means ± s.d. of at least three independent experiments. *Po0.05;
**Po0.01; ***Po0.001; ****Po0.0001.
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Cavin-1 has been also reported to have a pivotal role for the
initiation of membrane repair upon injury in skeletal
muscle.86 In mouse skeletal muscle we recognized Cavin-1
localizing in the mononucleated cell elements (i.e., SCs)
surrounding the myofibers as well as at the plasmalemma of
differentiated myofibers. During the ex vitro experiments
ideally resembling the process of muscle regeneration
occurring in vivo, when upon injury SCs escape quiescence
and proliferate toward the damaged site to differentiate into
newly formed myofibers, we observed increased protein levels
of Cavin-1 in both the cytosolic and membranous fractions of
SCs committed toward differentiation, therefore suggesting
that Cavin-1 could be especially required for skeletal muscle
formation during embryogenesis and muscle repair in the
adult life.
Skeletal muscle also represents one of the major source of
cell precursors that, in the presence of genetic lesions, may
undertake a tumorigenic route resulting in the development
of RMS, the most frequent soft tissue tumor of childhood.1–3
In this context, we found Cavin-1 expression to be always
matching with Cav-1 and Cav-2 in proliferating human lines
and mouse primary cultures established from tumors
occurring in transgenic mice that faithfully recapitulate the
appearance and progress of RMS.10,13 We detected a slight
difference in the molecular weight of human and mouse
Cavin-1 forms (i.e., 43.5 vs 50 kDa, respectively), suggesting
the potential occurrence of posttranslational modifications.
In this regard, one N-terminal acetylation site and four
phosphorylation sites localized to Ser-36, Ser-40, Ser-365 and
Ser-366 have been mapped along Cavin-1 sequence.76 Cavin-
1 exhibited a broad subcellular localization in both human
and mouse RMS cultures, ranging from nuclei and cytosol to
plasma membrane. Unlike the muscle cells, the defective
differentiation program observed in cancerous RMS cell
elements2 was characterized by downregulation of Cavin-1,
Cav-1 and Cav-2 expression.
In different types of cancer, including breast cancer,87 lung
cancer88 and prostate cancer,89 the role of Cavin-1 is gradually
assuming significant proportions and recent lines of evidence
have put forward its dual behavior. For example, Cavin-1 was
reported to decrease the malignant behavior of prostate PC3
cancer cells through different mechanisms,89–93 although
being essential for the tumor-promoting effect of Cav-1 in
pancreatic cancer94 and for multidrug resistance in breast
cancer lines.95 By analogy, even the role of Cav-1 in cancer
appears to be ambiguous, because Cav-1 may behave as either
a tumor suppressor or oncopromoter depending on the type
of tumor.96–101
Our data argue for an important role of Cavin-1 as essential
partner of Cav-1 in RMS progression, as we clearly observed
that loss of either Cavin-1 or Cav-1 was sufficient to impair
cell proliferation, migration and anchorage-independent cell
growth, a characteristic predictive of cell transformation
in vitro and in vivo. Consistent with this, we also found that
an incremental expression of Cavin-1 in RD cells, as causally
obtained upon Cav-1 overexpression, led to a very aggressive
cell behavior, which was characterized by a remarkable
anchorage-independent cell growth. Hence, the plasma
membrane interaction of Cavin-1 and Cav-1 may represent
an important initiation signal for specific downstream
pathways underlying the proliferation, migration and survival
of RMS cells. In this context, the formation of Cavin-1 and
Cav-1 complexes has been shown to promote a p53-
dependent premature senescence in fibroblasts exposed to
oxidative stress102,103 and to regulate the internalization of
IGF1R in human Hacat cells.104,105 Hence, it will be
important to assess whether Cavin-1 and Cav-1 complexes
may influence specific targets, such as p53 and IGF1R, that
play a central role in RMS progression.17,106
It is also of interest that we found Cavin-1 colocalizing with
Cav-2 in proliferating RMS cells. Although we primarily
focused on the interaction between Cavin-1 and Cav-1, a
potential involvement of Cavin-1 and Cav-2 complexes in
RMS cell survival and cancerous behavior cannot be ruled out.
Overall, the data of this work indicate Cavin-1 and Cav-1 as
potential molecular targets for counteracting the prolifera-
tion, migration and clonogenic potential of RMS cells.
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